Vistagen Therapeutics amends executive severance plan, expanding non-change-in-control benefits
Vistagen Therapeutics' board approved an amended and restated Change in Control Executive Severance Plan effective October 7, 2026. The plan now provides certain severance benefits for an Eligible Employee terminated without Cause even when the termination is not connected to a Change in Control. The filing covers executive compensation terms and does not report financial results or a change in leadership.
Key points
- Board approved the amended and restated plan on October 7, 2026; the original plan was adopted effective August 11, 2026.
- Qualifying Termination now covers termination without Cause or resignation for Good Reason from three months before to eighteen months after a Change in Control.
- Non-Change in Control benefits include a lump-sum payment of monthly base salary times the severance period, plus COBRA premium payments, subject to a release of claims.
- Each current executive officer is an Eligible Employee; eligibility requires at least 12 months of full-time employment.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.